You need to login...
If you are not registered...
| Subscribe to Krixos Health: | |
|
or call us on: +43 (0)1 27 63 015 or email: subscribe@krixos.com |
|
Most viewed
- 1. ASX Runners: Entertainment Rewards, Litchfield, Morella and TrivarX
- 2. Outrage over celebrity revels at South Korean breast cancer event
- 3. Marengo Presents Initial Phase 2 Results Demonstrating Broad Single-Agent Activity of Invikafusp Alfa Across Multiple PD-1-Refractory or -Resistant Solid Tumors as a Late-Breaking Oral Presentation at ESMO 2025
- 4. Roche's phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer
- 5. New generation of Antibody-Drug Conjugates (ADCs) shows unprecedented promise in early-stage disease
- 6. Junshi Biosciences Announces FDA's Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients
- 7. Dosimetric Evaluation of Tangential Arc and Jaw Tracking Techniques in Volumetric Modulated Arc Therapy for Synchronous Bilateral Breast Cancer
- 8. Multi-Modality Ultrasound Model for Renal Fibrosis Assessment in Chronic Kidney Disease: Integrating Grayscale and Color Doppler Ultrasound Radiomics with Shear Wave Elastography
- 9. Chemical linked to low sperm count, obesity and cancer found in dummies, tests find
Last updated at 17:35 GMT
Hot News Makers
Health/Pharma Companies
-
77021.17
-
24046.08
-
8905.21
-
6167.68
-
2659.66
-
1573.36
-
1234.77
-
525.35
-
316.55
-
263.09
Drugs, Treatments, Trials
-
37223.93
-
26008.65
-
12394.33
-
12149.78
-
8743.24
-
7844.16
-
7618.23
-
4678.08
-
2540.99
-
1880.96
Last updated at 17:10 GMT
